Pharmalucence Builds New Drug Production Facility in Massachusetts
"Pharmalucence has long maintained a strong radiopharmaceutical business in Massachusetts," said Glenn Alto, president and CEO of Pharmalucence. "We are investing to fully replace and modernize our infrastructure to ensure we maintain our local presence going forward."
The investment was aided by a $20 million bond issued by MassDevelopment, the first use of the Recovery Zone Facility Bond program in the state. The bond is one component of the American Recovery and Reinvestment Act to stimulate the economy with low-cost financing.
Pharmalucence produces eight drugs to treat cancers and heart disease. Construction on the new facility will begin this summer, and the plant is expected to be operational by the end of 2012.
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
A Heightened Focus on Reshoring
Site Selection 2020: The Importance of “Regional Depth” with Global Reach
COVID-19 and Site Selection in the Near and Long Term
34th Annual Corporate Survey & the 16th Annual Consultants Survey